DIADIA0.62%
SPYSPY0.28%
QQQQQQ0.03%
Trending
Top trending tickerADBEADBE4.02%
SPYSPY0.28%
DIADIA0.62%
VELOVELO4.21%
RKLBRKLB7.32%
DXYZDXYZ5.27%
KORUKORU5.74%
SATSSATS3.85%
XOVRXOVR2.64%
CRWVCRWV3.72%
Top trending tickerADBEADBE4.02%
SPYSPY0.28%
DIADIA0.62%
VELOVELO4.21%
RKLBRKLB7.32%
DXYZDXYZ5.27%
KORUKORU5.74%
SATSSATS3.85%
XOVRXOVR2.64%
CRWVCRWV3.72%
homeSymbolINKTnews
INKT logo

INKTMiNK Therapeutics Inc

$12.34
$0.145
(1.19%)
Today
Closed $12.34
$0.245
(1.99%)
After Hours
Updated: 07:00 PM EDT
Reported EarningsMay 15
Mkt Cap$60.73M
Vol108,857.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

News
all
press releases
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company PR Newswire SAN FRANCISCO, June 2, 2026 Equity Insider News CommentaryIssued on behalf of GT Biopharma, Inc. (NASDAQ: GTBP)SAN FRANCISCO, June 2...
PR Newswire
News Placeholder
More News
News Placeholder
Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the first disclosure of Phase 2 data from the C-800-23 study evaluating botensilimab (BOT), Agenus multifunctional Fc-enhanced anti-CTLA-4 antibody, with balstilimab (BAL), an anti-PD-1 antibody, in patients with...
Business Wire
News Placeholder
Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced new retrospective data showing that Noetiks artificial intelligence-based TARIO-2 model identified spatial tumor microenvironment patterns associated with clinical outcomes from routine pretreatment tumor pathology...
Business Wire
News Placeholder
Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the publication of Phase 1b data evaluating botensilimab (BOT), an Fc-enhanced anti-CTLA-4 antibody, in combination...
Business Wire
News Placeholder
Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today reported financial results for the first quarter ended March 31, 2026, and provided an operational update on botensilimab...
Business Wire
News Placeholder
MiNK Therapeutics, Inc. (NASDAQ:INKT) Given Consensus Recommendation of "Hold" by Analysts
MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) has received an average rating of "Hold" from the five analysts that are presently covering the company, Marketbeat.com reports. One analyst...
MarketBeat
News Placeholder
Short Interest in MiNK Therapeutics, Inc. (NASDAQ:INKT) Drops By 30.6%
MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) was the target of a significant decline in short interest in April. As of April 15th, there was short interest totaling 96,493 shares, a...
MarketBeat
News Placeholder
MiNK Therapeutics (NASDAQ:INKT) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen upgraded shares of MiNK Therapeutics to a "sell" rating in a research note on Saturday...
MarketBeat
News Placeholder
MiNK Therapeutics, Inc. (NASDAQ:INKT) Given Average Recommendation of "Hold" by Brokerages
MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) has received a consensus rating of "Hold" from the five research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a b...
MarketBeat
News Placeholder
HC Wainwright Issues Positive Outlook for INKT Earnings
MiNK Therapeutics, Inc. (NASDAQ:INKT - Free Report) - Equities researchers at HC Wainwright increased their Q1 2026 earnings per share estimates for shares of MiNK Therapeutics in a note issued to investors on Wednesday, April 1st. HC Wainwright analyst E. Bodnar now expects that the company will po...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.